A bacteriophage journey at the European Medicines Agency.
about
Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting DiseasesBacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria.Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome.Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy."French Phage Network"-Second Meeting ReportNimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?Guidelines to Compose an Ideal Bacteriophage Cocktail.Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.1st German Phage Symposium-Conference Report.Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia.
P2860
Q28069939-47168634-FDA3-4325-BD29-EDDBC08E76E9Q38776514-A9EF693B-ED83-47BE-8DCA-96968A24FC9FQ40119098-3ECFDFA4-8A9A-4BA1-AD0A-8483B511EA17Q41989580-C81CBABB-4BF0-4130-B342-B364EC21B024Q42357412-0AA49EA7-1D2C-4BA6-911D-BFE1D65F92E6Q46268031-793311DB-D024-4AB2-AF8A-9DEA7081EC26Q50016951-3B56F1DB-8E1C-4DFA-9E28-9842CBB22902Q50100609-0E1212EE-8081-48CF-8979-47A3EA083AC6Q52431831-037C3625-94FC-4882-8F96-1E84D5EB7911Q52622270-4AE29CA9-5839-4FC8-942D-96CD0AE33EA7Q55193419-5AC5788F-1F24-4FFA-BCB7-EB11B289AA94
P2860
A bacteriophage journey at the European Medicines Agency.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A bacteriophage journey at the European Medicines Agency.
@en
type
label
A bacteriophage journey at the European Medicines Agency.
@en
prefLabel
A bacteriophage journey at the European Medicines Agency.
@en
P2093
P2860
P50
P356
P1476
A bacteriophage journey at the European Medicines Agency.
@en
P2093
Christine Rohde
Daniel De Vos
Dirk Schoonjans
Gilbert Verbeken
Jean-Paul Pirnay
Maia Merabishvili
Martin Zizi
Olivier Patey
P2860
P304
P356
10.1093/FEMSLE/FNV225
P577
2015-12-10T00:00:00Z